Press Release

 

River Stone Biotech Inc. participates in DCAT 2022  conference and announces its ambition in becoming a global provider of substance abuse APIs.

 

Cambridge, April 28, 2022

River Stone Biotech Inc., MA, US (RSB) is excited to announce the use of its transformational technology in the manufacture of buprenorphine and other n-demethylation products including naloxone and naltrexone. The novel patent-protected technology employed will allow reliable supply of these vital APIs at much superior value – both economically and environmentally – to those available in the market today.

The technology employs a combination of state-of-the-art synthetic biology followed by other more traditional production methods; this novel approach eliminates the high cost and environmentally challenging production steps used traditionally.

RSB intends to be in full, world scale commercial production within three years and was pleased with the reception it received at select meetings during the recent DCAT New York conference when this ambition was unveiled.

About River Stone Biotech Inc.

RSB is headquartered in Cambridge, MA, US with development sites in Denmark and Australia; its highly experienced management team has taken multiple projects from concept through method development and into commercial-scale production.  RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes.

In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance Abuse Prevention programs around the world.

River Stone works with a small number of global providers to establish a virtual  cross-functional operation to enable its API offering.

 

For further information please contact:

Simon Ball
River Stone Biotech Inc.

simonb@rstbio.com